原发性肝癌转化治疗研究进展及展望
Research Progress and Prospects of Conversion Therapy for Primary Liver Cancer
DOI: 10.12677/ACM.2022.12121683, PDF,   
作者: 祝训浩*, 王乾昌, 刘方峰#：山东第一医科大学附属省立医院肝胆外科，山东 济南；刘 蔚*：哈尔滨医科大学附属第一医院，黑龙江 哈尔滨
关键词: 肝细胞肝癌；转化治疗；进展；展望；Hepatocellular Carcinoma； Conversion Therapy； Progress； Prospect
摘要: 原发性肝癌是临床中最常见的恶性肿瘤之一。由于其早期缺乏典型的临床表现，我国大多数病人确诊时已达中晚期，预后较差。因此通过相关治疗手段将不可切除肝癌转化为可切除肝癌的探索是十分有必要的。近年来，随着肝动脉栓塞化疗(TACE)及肝动脉灌注化疗(HAIC)等介入治疗技术的不断进步完善，新的靶向及免疫药物投入临床实验及应用，为肝癌转化治疗更新和发展带来了新的机遇和挑战。本综述旨在对目前肝癌转化治疗的现状和进展进行讨论，为肝癌的临床治疗提供一定参考。
Abstract: Primary liver cancer is one of the most common malignant tumors in clinical practice. Due to the lack of typical clinical manifestations in its early stage, most patients in China are already in the middle and late stages when diagnosed, and the prognosis is poor. Therefore, it is necessary to ex-plore the transformation of unresectable hepatocellular carcinoma into resectable hepatocellular carcinoma through relevant therapeutic means. In recent years, with the continuous improvement of interventional techniques such as transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC), new targeted and immune drugs have been put into clinical trials and clinics, which bring new opportunities and challenges for the update and development of hepatocellular carcinoma translational therapy. This review aims to discuss the current status and progress of translational therapy for hepatocellular carcinoma and provide some reference for the clinical treatment of hepatocellular carcinoma.
文章引用：祝训浩, 刘蔚, 王乾昌, 刘方峰. 原发性肝癌转化治疗研究进展及展望[J]. 临床医学进展, 2022, 12(12): 11680-11685. https://doi.org/10.12677/ACM.2022.12121683

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[3] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Sta-tistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[4] 赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京) [J]. 临床肝胆病杂志, 2022, 38(8): 1739-1758+1954-1967.
[5] 南月敏, 高沿航, 王荣琦, 李文刚, 赵素贤, 杨明. 原发性肝癌二级预防共识(2021年版) [J]. 临床肝胆病杂志, 2021, 37(3): 532-542.
[6] Petrick, J.L., Florio, A.A., Znaor, A., et al. (2020) Interna-tional Trends in Hepatocellular Carcinoma Incidence, 1978-2012. International Journal of Cancer, 147, 317-330. [Google Scholar] [CrossRef] [PubMed]
[7] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[8] 管颜青. 2040年全球肝癌新发病例将增55% [N]. 医师报, 2022-10-13(B02).
[9] Park, J.W., Chen, M., Colombo, M., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International: Official Journal of the International Association for the Study of the Liver, 35, 2155-2166. [Google Scholar] [CrossRef] [PubMed]
[10] Ryerson, A.B., Eheman, C.R., Altekruse, S.F., et al. (2016) Annual Report to the Nation on the Status of Cancer, 1975-2012, Featuring the Increasing Incidence of Liver Cancer. Cancer, 122, 1312-1337. [Google Scholar] [CrossRef] [PubMed]
[11] 原发性肝癌诊疗规范(2019年版) [J]. 中国实用外科杂志, 2020, 40(2): 121-138.
[12] Sun, H.C., Zhou, J., Wang, Z., et al. (2022) Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition). Hepatobiliary Surgery and Nutrition, 11, 227-252. [Google Scholar] [CrossRef] [PubMed]
[13] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版) [J]. 中华消化外科杂志, 2021, 20(6): 600-616.
[14] Zhu, S.L., Zhong, J.H., Ke, Y., Ma, L., You, X.M. and Li, L.Q. (2015) Efficacy of Hepatic Resection vs Transarterial Chemoembolization for Solitary Huge Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 9630-9637. [Google Scholar] [CrossRef] [PubMed]
[15] 彭一晟, 何攀, 朱刚, 等. CalliSpheres载药微球与传统经肝动脉化疗栓塞术治疗肝细胞癌效果和安全性比较的Meta分析[J]. 临床肝胆病杂志, 2021, 37(8): 1841-1847.
[16] Luz, J., Veloso Gomes, F., Costa, N.V., et al. (2021) BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer—A Randomized Controlled Trial Comparing Portal Vein Embolization with N-Butyl-Cya- noacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils. Radiology, 299, 715-724. [Google Scholar] [CrossRef] [PubMed]
[17] 倪俊声, 李曜, 葛乃建, 等. ALPPS与采用不同栓塞材料PVE对肝再生及手术切除率影响研究[J]. 中国实用外科杂志, 2021, 41(9): 1043-1048+1055.
[18] Chan, A., Zhang, W.Y., Chok, K., et al. (2021) ALPPS versus Portal Vein Embolization for Hepatitis-Related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant before Major Hepatectomy. Annals of Surgery, 273, 957-965. [Google Scholar] [CrossRef] 
[19] Schnitzbauer, A.A., Lang, S.A., Goessmann, H., et al. (2012) Right Portal Vein Ligation Combined with in Situ Splitting Induces Rapid Left Lateral Liver Lobe Hyper-trophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings. Annals of Surgery, 255, 405-414. [Google Scholar] [CrossRef] 
[20] Cai, X., Tong, Y., Yu, H., et al. (2017) The ALPPS in the Treatment of Hepatitis B-Related Hepatocellular Carcinoma with Cirrhosis: A Single-Center Study and Literature Review. Surgical innovation, 24, 358-364. [Google Scholar] [CrossRef] [PubMed]
[21] Lang, H. (2020) ALPPS—Beneficial or Detrimental. Surgical Oncology, 33, 249-253. [Google Scholar] [CrossRef] [PubMed]
[22] Li, Q.J., He, M.K., Chen, H.W., et al. (2022) Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 40, 150-160. [Google Scholar] [CrossRef] 
[23] Zhu, X.D., Huang, C., Shen, Y.H., et al. (2021) Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 10, 320-329. [Google Scholar] [CrossRef] [PubMed]
[24] 韦滔, 唐置鸿, 韦猛, 等. TACE联合TKI及PD-1抑制剂在不可切除肝细胞癌患者转化治疗中的疗效[J]. 中国癌症防治杂志, 2021, 13(4): 413-419.
[25] Ren, Z., Xu, J., Bai, Y., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study. The Lancet. Oncology, 22, 977-990. [Google Scholar] [CrossRef] 

为你推荐